{"id":"bromocriptine-mesylate-tablets","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Nausea"},{"rate":"15-25","effect":"Headache"},{"rate":"10-20","effect":"Dizziness"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-15","effect":"Orthostatic hypotension"},{"rate":"5-10","effect":"Constipation"},{"rate":"5-10","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bromocriptine acts as a dopamine agonist at D2 receptors in the tuberoinfundibular pathway, suppressing prolactin release from the anterior pituitary gland. This mechanism makes it effective for treating hyperprolactinemia and prolactin-secreting adenomas. Additionally, dopamine agonism in other brain regions contributes to its effects in movement disorders and metabolic conditions.","oneSentence":"Bromocriptine mesylate is a dopamine D2 receptor agonist that inhibits prolactin secretion and modulates hypothalamic-pituitary function.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:42:11.231Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperprolactinemia"},{"name":"Prolactin-secreting pituitary adenoma (prolactinoma)"},{"name":"Acromegaly (adjunctive therapy)"},{"name":"Parkinson's disease (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT07124221","phase":"PHASE3","title":"A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-09-12","conditions":"Hyperprolactinemia","enrollment":382},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT04413344","phase":"PHASE1, PHASE2","title":"Repurposing Bromocriptine for Abeta Metabolism in Alzheimer's Disease","status":"COMPLETED","sponsor":"Kyoto University","startDate":"2020-06-05","conditions":"Familial Alzheimer Disease (FAD), PSEN1 Mutation","enrollment":8},{"nctId":"NCT00650520","phase":"PHASE1","title":"Fed Study of (Parlodel®) 2.5 mg Bromocriptine Mesylate Tablets","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2007-05","conditions":"Healthy","enrollment":119},{"nctId":"NCT02682901","phase":"PHASE4","title":"Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Eastern Virginia Medical School","startDate":"2015-10-05","conditions":"Diabetic Autonomic Neuropathy","enrollment":84},{"nctId":"NCT00998556","phase":"PHASE2","title":"Effect of Bromocriptine on Left Ventricular Function in Women With Peripartum Cardiomyopathy","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2010-06","conditions":"Peripartum Cardiomyopathy","enrollment":64},{"nctId":"NCT04181385","phase":"PHASE2, PHASE3","title":"Acute Olanzapine and Lipid Response","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2019-01-01","conditions":"Healthy","enrollment":15},{"nctId":"NCT01474018","phase":"PHASE4","title":"QR-Bromocriptine as an Adjunct to Insulin and Metformin in the Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2011-11","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT02299050","phase":"PHASE4","title":"Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-06","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT03714763","phase":"NA","title":"Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-11-01","conditions":"Pituitary Adenoma","enrollment":50},{"nctId":"NCT01821001","phase":"PHASE1","title":"Vaginal Bromocriptine for Treatment of Adenomyosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2013-03","conditions":"Adenomyosis","enrollment":1},{"nctId":"NCT01673724","phase":"PHASE4","title":"Pramipexole and Bromocriptine on Nonmotor Symptoms of Early Parkinson's Disease","status":"COMPLETED","sponsor":"Sandoz","startDate":"2012-02","conditions":"Parkinson's Disease","enrollment":121},{"nctId":"NCT02078440","phase":"PHASE1","title":"Pharmacokinetic Study of CYCLOSET ® 0.8 mg Tablets in Children and Adolescent Type 2 Diabetes Mellitus Subjects","status":"COMPLETED","sponsor":"VeroScience","startDate":"2014-01","conditions":"Type 2 Diabetes","enrollment":18},{"nctId":"NCT00377676","phase":"PHASE3","title":"Safety and Tolerability Study of Cycloset in Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"VeroScience","startDate":"2004-07","conditions":"Type 2 Diabetes Mellitus","enrollment":3095},{"nctId":"NCT00441363","phase":"PHASE3","title":"Efficacy and Safety of Cycloset® Compared With Placebo When Added to Metformin","status":"TERMINATED","sponsor":"VeroScience","startDate":"2005-02","conditions":"Type 2 Diabetes","enrollment":66},{"nctId":"NCT00240409","phase":"PHASE3","title":"Randomized Single-blind Placebo Controlled Comparative Trial of Pramipexole and Bromocriptine in Parkinson's Disease","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2003-07","conditions":"Parkinson Disease","enrollment":208}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Bromocriptine mesylate tablets","genericName":"Bromocriptine mesylate tablets","companyName":"Changchun GeneScience Pharmaceutical Co., Ltd.","companyId":"changchun-genescience-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bromocriptine mesylate is a dopamine D2 receptor agonist that inhibits prolactin secretion and modulates hypothalamic-pituitary function. Used for Hyperprolactinemia, Prolactin-secreting pituitary adenoma (prolactinoma), Acromegaly (adjunctive therapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}